Fresenius Kabi has divested its Chilean subsidiary Laboratorio Sanderson to Peru’s Medifarma, as part of efforts to streamline the German injectables giant’s manufacturing operations.
The transaction includes the transfer of an intravenous drug facility in Santiago de Chile, a move that Fresenius said would contribute towards “streamlining the production network of its operating company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?